Protocol Name: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS-IGAN). (Omeros)
Indication: Immunoglobin nephropathy – IgA
Primary Investigator: Dr. Akinwande Akinfolarin
Location: 411 N Washington Ave, Suite 6000, Dallas, TX 75204